CTD Holding’s Trappsol Cyclodextrin trial is currently enrolling in two trial sites: Oakland, US and Manchester, UK. The Phase 1 trial in the US requires patients to be 18+ and is looking to recruit approximately 12 patients for a research study lasting up to 20 weeks. The Phase 1/2 trial in the UK is also looking to recruit approximately 12 patients in a research study for up to 56 weeks in total, but patients can be 2 years or older. There is further information on the trial.gov site. Both are double blinded trials but only with regard to the dosage given, there is no sham/placebo in these trials, everyone enrolled gets the drug.